AQR Capital Management’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-2,361
| Closed | -$406K | – | 2338 |
|
|
2021
Q3 | $406K | Sell |
2,361
-2,012
| -46% | -$263K | ﹤0.01% | 1939 |
|
|
2021
Q2 | $539K | Sell |
4,373
-10,050
| -70% | -$1.27M | ﹤0.01% | 1868 |
|
|
2021
Q1 | $1.96M | Buy |
14,423
+1,736
| +14% | +$224K | ﹤0.01% | 1217 |
|
|
2020
Q4 | $1.59M | Buy |
12,687
+9,291
| +274% | +$1.09M | ﹤0.01% | 1286 |
|
|
2020
Q3 | $382K | Sell |
3,396
-27,853
| -89% | -$2.77M | ﹤0.01% | 1834 |
|
|
2020
Q2 | $2.98M | Buy |
31,249
+4,431
| +17% | +$427K | ﹤0.01% | 989 |
|
|
2020
Q1 | $2.41M | Buy |
26,818
+21,818
| +436% | +$1.7M | ﹤0.01% | 1012 |
|
|
2019
Q4 | $265K | Buy |
+5,000
| New | +$228K | ﹤0.01% | 1939 |
|
|
2019
Q1 | – | Sell |
-9,255
| Closed | -$403K | – | 2253 |
|
|
2018
Q4 | $403K | Buy |
9,255
+2,155
| +30% | +$108K | ﹤0.01% | 1860 |
|
|
2018
Q3 | $406K | Sell |
7,100
-4,639
| -40% | -$228K | ﹤0.01% | 2016 |
|
|
2018
Q2 | $570K | Buy |
11,739
+2,202
| +23% | +$80.2K | ﹤0.01% | 1934 |
|
|
2018
Q1 | $373K | Buy |
+9,537
| New | +$405K | ﹤0.01% | 2001 |
|
|
2017
Q1 | – | Sell |
-18,568
| Closed | -$474K | – | 2277 |
|
|
2016
Q4 | $474K | Sell |
18,568
-1,859
| -9% | -$58.9K | ﹤0.01% | 1950 |
|
|
2016
Q3 | $739K | Buy |
+20,427
| New | +$677K | ﹤0.01% | 1827 |
|
|
2015
Q3 | – | Sell |
-6,700
| Closed | -$212K | – | 2293 |
|
|
2015
Q2 | $212K | Hold |
6,700
| – | – | ﹤0.01% | 2095 |
|
|
2015
Q1 | $255K | Sell |
6,700
-12,200
| -65% | -$485K | ﹤0.01% | 1941 |
|
|
2014
Q4 | $736K | Buy |
+18,900
| New | +$659K | ﹤0.01% | 1790 |
|
|
2014
Q2 | – | Sell |
-105,000
| Closed | -$3.62M | – | 2609 |
|
|
2014
Q1 | $3.62M | Buy |
+105,000
| New | +$4.74M | 0.01% | 989 |
|
AQR Capital Management's XLRN Position: Q4 2021 in Review
AQR Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 2,361 shares — an estimated $406K sold.
AQR Capital Management first reported a position in XLRN in Q1 2014 and held it in 18 quarters. The position peaked at $3.62M in Q1 2014. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- AQR Capital Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- AQR Capital Management sold 2,361 Acceleron Pharma shares in Q4 2021, an estimated $406K.
- AQR Capital Management first reported a position in Acceleron Pharma in Q1 2014 and held it in 18 quarters.
- AQR Capital Management's Acceleron Pharma position peaked at $3.62M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on AQR Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.